Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...

For the first time, a team of experts from the Technical University of Munich (TUM), RWTH Aachen University, and the German ...

The deal is the second Chinese oncology pact in as many weeks for AbbVie, which also committed $175 million for a ...

Men with newly diagnosed multiple myeloma are twice as likely as women to have stage III disease, with more kidney damage and ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

A new study by the National Cancer Research Centre (CNIO) has identified several sets of genes related to the predisposition ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Patient-reported fatigue prior to cancer treatment could be used as a biomarker for identifying which individuals will develop serious or fatal adverse events.A retrospective analysis showed patients ...

The relationship between inflammation and cancer represents one of the central paradoxes in modern tumor immunology. On one hand, chronic inflammation is a ...

TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...